New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
14:41 EDTACT, QCOR, MNKFDA approval of generic Exalgo negative for Mallinckrodt, says BMO Capital
BMO Capital thinks the FDA's approval of Actavisí (ACT) generic version of Exalgo was expected, but the firm still views it as a near-term negative for Mallinckrodt (MNK). BMO expects Mallinckrodt's raised guidance and pending accretive Questcor (QCOR) deal to support the stock longer-term and maintains an Outperform rating on Mallinckrodt.
News For ACT;QCOR;MNK From The Last 14 Days
Check below for free stories on ACT;QCOR;MNK the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 25, 2014
10:02 EDTQCOROn The Fly: Analyst Downgrade Summary
Subscribe for More Information
06:22 EDTQCORQuestcor downgraded to Perform from Outperform at Oppenheimer
July 24, 2014
09:10 EDTQCORQuestcor expects insurance coverage for Acthar to remain favorable, consistent
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 H.P. Acthar gel sales up 39% to $188.5M
Subscribe for More Information
09:10 EDTQCORQuestcor reports Q2 adjusted EPS $1.85, consensus $1.74
Subscribe for More Information
July 23, 2014
10:02 EDTACT, MNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTMNK, ACTDeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:09 EDTACTActavis initiated with a Buy at Deutsche Bank
Subscribe for More Information
16:09 EDTMNKMallinckrodt initiated with a Buy at Deutsche Bank
Subscribe for More Information
July 21, 2014
16:36 EDTACTActavis and Medicines360 announce FDA acceptance of Levosert NDA
Subscribe for More Information
07:36 EDTMNK, QCORMallinckrodt price target raised to $95 from $85 at Jefferies
Subscribe for More Information
July 17, 2014
15:42 EDTACTDepomed says Actavis preliminarily enjoined from marketing generic Gralise
Subscribe for More Information
11:12 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
10:00 EDTMNKOn The Fly: Analyst Initiation Summary
Subscribe for More Information
July 16, 2014
16:13 EDTQCOR, MNKMallinckrodt initiated with an Outperform, $100 target at Oppenheimer
Oppenheimer believes Mallinckrodt's (MNK) acquisition of Questcor (QCOR) provides sustainable high-growth revenue potential. It believes the company bought Acthar at an attractive valuation. Opco started shares of Mallinckrodt with an Outperform rating and $100 price target.
16:09 EDTMNKMallinckrodt initiated with an Outperform at Oppenheimer
Target $100.
11:28 EDTACTLeon Cooperman gives 12 stock picks at CNBC conference
Subscribe for More Information
11:16 EDTACTCooperman lists Actavis, Citigroup, KKR among top-picks, CNBC says
Subscribe for More Information
10:35 EDTQCOROptions with decreasing implied volatility
Subscribe for More Information
09:12 EDTACTLeerink healthcare analyst holds an analyst/industry conference call
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use